Wall Street analysts expect that Verrica Pharmaceuticals Inc (NASDAQ:VRCA) will announce ($0.27) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Verrica Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.26) and the lowest estimate coming in at ($0.28). The firm is scheduled to report its next quarterly earnings report on Wednesday, February 6th.
According to Zacks, analysts expect that Verrica Pharmaceuticals will report full-year earnings of ($1.17) per share for the current financial year, with EPS estimates ranging from ($1.42) to ($0.75). For the next fiscal year, analysts expect that the company will post earnings of ($1.02) per share, with EPS estimates ranging from ($1.25) to ($0.90). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Verrica Pharmaceuticals.
Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its quarterly earnings data on Wednesday, November 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03).
Separately, Zacks Investment Research cut shares of Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, September 20th.
Shares of NASDAQ VRCA opened at $10.86 on Monday. Verrica Pharmaceuticals has a twelve month low of $10.80 and a twelve month high of $23.29.
In other Verrica Pharmaceuticals news, COO Linda Palczuk purchased 2,500 shares of the stock in a transaction on Monday, September 17th. The shares were purchased at an average cost of $16.52 per share, for a total transaction of $41,300.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Paul B. Manning purchased 70,200 shares of the stock in a transaction on Tuesday, November 13th. The stock was acquired at an average price of $14.15 per share, for a total transaction of $993,330.00. The disclosure for this purchase can be found here.
A number of hedge funds have recently modified their holdings of VRCA. Bank of New York Mellon Corp acquired a new stake in Verrica Pharmaceuticals in the 3rd quarter valued at $195,000. Laurion Capital Management LP acquired a new position in shares of Verrica Pharmaceuticals during the 2nd quarter worth about $395,000. Dean Capital Investments Management LLC acquired a new position in shares of Verrica Pharmaceuticals during the 2nd quarter worth about $676,000. Asymmetry Capital Management L.P. acquired a new position in shares of Verrica Pharmaceuticals during the 2nd quarter worth about $1,184,000. Finally, Point72 Asset Management L.P. acquired a new position in shares of Verrica Pharmaceuticals during the 3rd quarter worth about $1,463,000. Hedge funds and other institutional investors own 32.07% of the company’s stock.
Verrica Pharmaceuticals Company Profile
Verrica Pharmaceuticals Inc develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790.
Featured Story: Understanding each part of a balance sheet
Get a free copy of the Zacks research report on Verrica Pharmaceuticals (VRCA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.